Landscapes and Dynamic Diversifications of B-cell Receptor Repertoires in COVID-19 Patients
Haitao Xiang,Yingze Zhao,Xinyang Li,Peipei Liu,Longlong Wang,Meiniang Wang,Lei Tian,Hai-Xi Sun,Wei Zhang,Ziqian Xu,Beiwei Ye,Xiaoju Yuan,Pengyan Wang,Ning Zhang,Yuhuan Gong,Chengrong Bian,Zhaohai Wang,Linxiang Yu,Jin Yan,Fanping Meng,Changqing Bai,Xiaoshan Wang,Xiaopan Liu,Kai Gao,Liang Wu,Longqi Liu,Ying Gu,Yuhai Bi,Yi Shi,Shaogeng Zhang,Chen Zhu,Xun Xu,Guizhen Wu,George F. Gao,Naibo Yang,William J. Liu,Penghui Yang
DOI: https://doi.org/10.1016/j.humimm.2021.10.007
IF: 2.211
2022-01-01
Human Immunology
Abstract:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the pandemic of coronavirus disease 2019 (COVID-19). Great international efforts have been put into the development of prophylactic vaccines and neutralizing antibodies. However, the knowledge about the B cell immune response induced by the SARS-CoV-2 virus is still limited. Here, we report a comprehensive characterization of the dynamics of immunoglobin heavy chain (IGH) repertoire in COVID-19 patients. By using next-generation sequencing technology, we examined the temporal changes in the landscape of the patient's immunological status and found dramatic changes in the IGH within the patient's immune system after the onset of COVID-19 symptoms. Although different patients have distinct immune responses to SARS-CoV-2 infection, by employing clonotype overlap, lineage expansion, and clonotype network analyses, we observed a higher clonotype overlap and substantial lineage expansion of B cell clones 2-3 weeks after the onset of illness, which is of great importance to B-cell immune responses. Meanwhile, for preferences of V gene usage during SARS-CoV-2 infection, IGHV3-74 and IGHV4-34, and IGHV4-39 in COVID-19 patients were more abundant than those of healthy controls. Overall, we present an immunological resource for SARS-CoV-2 that could promote both therapeutic development as well as mechanistic research. (c) 2021 Published by Elsevier Inc. on behalf of American Society for Histocompatibility and Immunogenetics.